사이넥시스(SCYX)는 NASDAQ에 상장된 Healthcare · Drug Manufacturers - Specialty & Generic 기업입니다. 현재가 $4.50 (+1.12%), 시가총액 $0.05B, 52주 최저~최고 $0.58 ~ $1.18.
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
사이넥시스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
사이넥시스의 현재 주가는 $4.50 (+1.12%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
사이넥시스의 시가총액은 약 $0.05B입니다.
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offer